Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men

Johannes D Veldhuis, Daniel M. Keenan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: GH pulses are putatively initiated by hypothalamic GH-releasing hormone (GHRH), amplified by GH-releasing peptide (GHRP), and inhibited by somatostatin (SS). Objective: To ascertain how secretagogues control the waveform (time evolution of release rates) as well as the mass of secretory bursts. Design: We quantified the shape of GH secretory bursts evoked by continuous combined i.v. infusion of maximally effective doses of GHRH and GHRP-2, and by bolus injection of each peptide after delivering L-arginine to restrain hypothalamic SS release in 12 healthy young men. Methods: A mathematically verified and experimentally validated variable-waveform deconvolution model was applied to intensively sampled GH time series. Results: The secretory-burst mode (time from burst onset to maximal secretion) was 19 ± 0.6 9 min during saline infusion, and fell to a) 10.4±3.Omin during constant dual stimulation with GHRH/GHRP-2 (P<0.01), b) 14.6±1.8min after L-arginine/GHRH (P<0.025), and c) 15.0± 1.0 min after L-arginine/GHRH (P<0.01). Secretagogues augmented the mass of GH secreted in pulses by 44-, 42-, and 16-fold respectively, over saline (2.2±0.81 μg/l per h; P<0.001 for each). Pulse number and variability were unaffected. Applying the same methodology to ten other young men with acute leuprolide-induced hypogonadism yielded comparable waveform and mass estimates. Conclusion: The present analyses in men demonstrate that peptidyl secretagogues modulate not only the magnitude but also the time course of the GH-release process in vivo independently of the short-term sex-steroid milieu.

Original languageEnglish (US)
Pages (from-to)547-554
Number of pages8
JournalEuropean Journal of Endocrinology
Volume159
Issue number5
DOIs
StatePublished - Nov 2008

Fingerprint

Hormones
Arginine
Somatostatin
Peptides
Leuprolide
Pituitary Hormone-Releasing Hormones
Hypogonadism
Steroids
Injections
peptide P

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. / Veldhuis, Johannes D; Keenan, Daniel M.

In: European Journal of Endocrinology, Vol. 159, No. 5, 11.2008, p. 547-554.

Research output: Contribution to journalArticle

@article{fc5a084abb63478cb23cfcdf8264ec72,
title = "Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men",
abstract = "Background: GH pulses are putatively initiated by hypothalamic GH-releasing hormone (GHRH), amplified by GH-releasing peptide (GHRP), and inhibited by somatostatin (SS). Objective: To ascertain how secretagogues control the waveform (time evolution of release rates) as well as the mass of secretory bursts. Design: We quantified the shape of GH secretory bursts evoked by continuous combined i.v. infusion of maximally effective doses of GHRH and GHRP-2, and by bolus injection of each peptide after delivering L-arginine to restrain hypothalamic SS release in 12 healthy young men. Methods: A mathematically verified and experimentally validated variable-waveform deconvolution model was applied to intensively sampled GH time series. Results: The secretory-burst mode (time from burst onset to maximal secretion) was 19 ± 0.6 9 min during saline infusion, and fell to a) 10.4±3.Omin during constant dual stimulation with GHRH/GHRP-2 (P<0.01), b) 14.6±1.8min after L-arginine/GHRH (P<0.025), and c) 15.0± 1.0 min after L-arginine/GHRH (P<0.01). Secretagogues augmented the mass of GH secreted in pulses by 44-, 42-, and 16-fold respectively, over saline (2.2±0.81 μg/l per h; P<0.001 for each). Pulse number and variability were unaffected. Applying the same methodology to ten other young men with acute leuprolide-induced hypogonadism yielded comparable waveform and mass estimates. Conclusion: The present analyses in men demonstrate that peptidyl secretagogues modulate not only the magnitude but also the time course of the GH-release process in vivo independently of the short-term sex-steroid milieu.",
author = "Veldhuis, {Johannes D} and Keenan, {Daniel M.}",
year = "2008",
month = "11",
doi = "10.1530/EJE-08-0414",
language = "English (US)",
volume = "159",
pages = "547--554",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "5",

}

TY - JOUR

T1 - Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men

AU - Veldhuis, Johannes D

AU - Keenan, Daniel M.

PY - 2008/11

Y1 - 2008/11

N2 - Background: GH pulses are putatively initiated by hypothalamic GH-releasing hormone (GHRH), amplified by GH-releasing peptide (GHRP), and inhibited by somatostatin (SS). Objective: To ascertain how secretagogues control the waveform (time evolution of release rates) as well as the mass of secretory bursts. Design: We quantified the shape of GH secretory bursts evoked by continuous combined i.v. infusion of maximally effective doses of GHRH and GHRP-2, and by bolus injection of each peptide after delivering L-arginine to restrain hypothalamic SS release in 12 healthy young men. Methods: A mathematically verified and experimentally validated variable-waveform deconvolution model was applied to intensively sampled GH time series. Results: The secretory-burst mode (time from burst onset to maximal secretion) was 19 ± 0.6 9 min during saline infusion, and fell to a) 10.4±3.Omin during constant dual stimulation with GHRH/GHRP-2 (P<0.01), b) 14.6±1.8min after L-arginine/GHRH (P<0.025), and c) 15.0± 1.0 min after L-arginine/GHRH (P<0.01). Secretagogues augmented the mass of GH secreted in pulses by 44-, 42-, and 16-fold respectively, over saline (2.2±0.81 μg/l per h; P<0.001 for each). Pulse number and variability were unaffected. Applying the same methodology to ten other young men with acute leuprolide-induced hypogonadism yielded comparable waveform and mass estimates. Conclusion: The present analyses in men demonstrate that peptidyl secretagogues modulate not only the magnitude but also the time course of the GH-release process in vivo independently of the short-term sex-steroid milieu.

AB - Background: GH pulses are putatively initiated by hypothalamic GH-releasing hormone (GHRH), amplified by GH-releasing peptide (GHRP), and inhibited by somatostatin (SS). Objective: To ascertain how secretagogues control the waveform (time evolution of release rates) as well as the mass of secretory bursts. Design: We quantified the shape of GH secretory bursts evoked by continuous combined i.v. infusion of maximally effective doses of GHRH and GHRP-2, and by bolus injection of each peptide after delivering L-arginine to restrain hypothalamic SS release in 12 healthy young men. Methods: A mathematically verified and experimentally validated variable-waveform deconvolution model was applied to intensively sampled GH time series. Results: The secretory-burst mode (time from burst onset to maximal secretion) was 19 ± 0.6 9 min during saline infusion, and fell to a) 10.4±3.Omin during constant dual stimulation with GHRH/GHRP-2 (P<0.01), b) 14.6±1.8min after L-arginine/GHRH (P<0.025), and c) 15.0± 1.0 min after L-arginine/GHRH (P<0.01). Secretagogues augmented the mass of GH secreted in pulses by 44-, 42-, and 16-fold respectively, over saline (2.2±0.81 μg/l per h; P<0.001 for each). Pulse number and variability were unaffected. Applying the same methodology to ten other young men with acute leuprolide-induced hypogonadism yielded comparable waveform and mass estimates. Conclusion: The present analyses in men demonstrate that peptidyl secretagogues modulate not only the magnitude but also the time course of the GH-release process in vivo independently of the short-term sex-steroid milieu.

UR - http://www.scopus.com/inward/record.url?scp=56749096817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749096817&partnerID=8YFLogxK

U2 - 10.1530/EJE-08-0414

DO - 10.1530/EJE-08-0414

M3 - Article

C2 - 18703567

AN - SCOPUS:56749096817

VL - 159

SP - 547

EP - 554

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 5

ER -